Annals of Oncology Q1 Unclaimed

Elsevier Ltd United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Annals of Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 294. It is an CC BY Journal with a Single blind Peer Review review system The scope of the journal is focused on Cancer, Oncology, Systemic anticancer therapy, Molecular pathology. It has an SJR impact factor of 13,942 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 13,942.

Annals of Oncology focuses its scope in these topics and keywords: cancer, patients, advanced, phase, lung, metastatic, clinical, treatment, trial, ii, ...

Type: Journal

Type of Copyright: CC BY

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -


- €

Inmediate OA


Embargoed OA

0 €

Non OA


Annals of Oncology


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)




No comments ... Be the first to comment!

Aims and Scope

cancer, patients, advanced, phase, lung, metastatic, clinical, treatment, trial, ii, study, breast, randomized, colorectal, cell, carcinoma, treated, nonsmallcell, cisplatin, iii, receptor, egfr, Cancer, Oncology, Systemic anticancer therapy, Molecular pathology

Best articles by citations

Screening for carcinomain situ in the contralateral testicle in patients with testicular cancer: a population-based study

View more

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease

View more

Coming into focus: the nonovarian origins of ovarian cancer

View more

Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes Project

View more

Psoriasiform lesions as paraneoplastic manifestation in Hodgkin's disease

View more

Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome

View more

Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin

View more

A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267

View more

The ESMO Precision Medicine Glossary

View more

The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients - the Polish Lymphoma Research Group (PLRG) Observational Study

View more

NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94)

View more

Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group

View more

Outcome in colorectal cancer - tumour, stroma and so much more

View more

ESMO-MCBS v1.1: statistical and patient-relevant shortcomings

View more

Early ultrasonographic finding of septic thrombophlebitis is the main indicator of central venous catheter removal to reduce infection-related mortality in neutropenic patients with bloodstream infection

View more

Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial

View more

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)

View more

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

View more

Faecal occult blood testing (FOBT) as screening for colorectal cancer: the current controversy

View more

Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer

View more

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

View more

PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?

View more

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

View more

Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer

View more